Prior presumed coronavirus infection reduces COVID-19 risk: A cohort study
- PMID: 33127456
- PMCID: PMC7590640
- DOI: 10.1016/j.jinf.2020.10.023
Prior presumed coronavirus infection reduces COVID-19 risk: A cohort study
Abstract
Background: Immunological cross-reactivity between common cold coronaviruses (CCC) and SARS-CoV-2 might account for the reduced incidence of COVID-19 in children. Evidence to support speculation includes in vitro evidence for humoral and cellular cross-reactivity with SARS-CoV-2 in specimens obtained before the pandemic started.
Method: We used retrospective health insurance enrollment records, claims, and laboratory results to assemble a cohort of 869,236 insured individuals who had a PCR test for SARS-CoV-2. We estimated the effects of having clinical encounters for various diagnostic categories in the year preceding the study period on the risk of a positive test result.
Findings: After adjusting for age, gender and care seeking behavior, we identified that individuals with diagnoses for common cold symptoms, including acute sinusitis, bronchitis, or pharyngitis in the preceding year had a lower risk of testing positive for SARS-CoV-2 (OR=0.76, 95%CI=0.75, 0.77). No reduction in the odds of a positive test for SARS-CoV-2 was seen in individuals under 18 years. The reduction in odds in adults remained stable for four years but was strongest in those with recent common cold symptoms.
Interpretation: While this study cannot attribute this association to cross-immunity resulting from a prior CCC infection, it is one potential explanation. Regardless of the cause, the reduction in the odds of being infected by SARS-CoV-2 among those with a recent diagnosis of common cold symptoms may have a role in shifting future COVD-19 infection patterns from endemic to episodic.
Keywords: Common cold; Covid-19; Cross reactive; SARS-Cov-2.
Copyright © 2020. Published by Elsevier Ltd.
Conflict of interest statement
Declaration of Competing Interest Drs. Overhage, Beachler and Lanes are employees of HealthCore Inc., a subsidiary of Anthem Inc. Dr. Aran is a consutlant for Anthem Innovation Israel. None of the authors have any competing interests.
Figures
Comment in
-
COVID-19 in a case previously infected with MERS-CoV: No cross immunity.J Infect. 2021 Mar;82(3):e28-e29. doi: 10.1016/j.jinf.2020.11.035. Epub 2020 Nov 30. J Infect. 2021. PMID: 33271173 Free PMC article. No abstract available.
-
Early seasonal coronavirus seroconversion did not produce cross-protective SARS-CoV-2 antibodies.J Infect. 2023 Jan;86(1):e10-e12. doi: 10.1016/j.jinf.2022.08.032. Epub 2022 Sep 5. J Infect. 2023. PMID: 36067868 Free PMC article.
References
-
- Paules C.I., Marston H.D., Fauci A.S. Coronavirus infections—more than just the common cold. JAMA. 2020;323(8):707–708. - PubMed
-
- de Wilde A.H., Snijder E.J., Kikkert M., van Hemert M.J. Roles of host gene and non-coding RNA expression in virus infection. Springer; 2017. Host factors in coronavirus replication; pp. 1–42.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
